Based on these findings, ginsenoside Rb1 could serve as a lead compound for developing targeted inhibitors to suppress Twist1 hyperactivation and biosynthesis, thereby providing novel therapeutic strategies for ventricular remodeling HF. This evidence concerns the gene TWIST1 and hydrops fetalis.